# Amneal Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/AMRX/amneal-reports-first-quarter-2026-financial-results
Ticker: AMRX
Company: Amneal Pharmaceuticals
Source: Amneal Pharmaceuticals
Published: 2026-05-07 20:01 EST
Original Source URL: https://investors.amneal.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 12:00 EST — [Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution](https://biopharmsignal.com/news/AMRX/amneal-announces-u-s-fda-approval-of-romidepsin-injection-solution) — Source: Amneal Pharmaceuticals
- 2026-06-01 12:00 EST — [Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/AMRX/amneal-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Amneal Pharmaceuticals
- 2026-05-07 20:01 EST — [Amneal Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/AMRX/amneal-reports-first-quarter-2026-financial-results) — Source: Amneal Pharmaceuticals
- 2026-04-22 10:00 EST — [Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance](https://biopharmsignal.com/news/AMRX/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance) — Source: Amneal Pharmaceuticals
- 2026-04-20 12:00 EST — [Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®](https://biopharmsignal.com/news/AMRX/amneal-announces-additional-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinson-s-disease-including-over-3-more-hours-of-daily-good-on-time-when-switching-from-rytaryr) — Source: Amneal Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)